The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers

Yasheng Huang, Xiyong Liu, Yuan Hung Wang, Shauh Der Yeh, Chi Long Chen, Rebecca A. Nelson, Peiguo Chu, Timothy Wilson, Yun Yen

研究成果: 雜誌貢獻文章

9 引文 (Scopus)

摘要

Purpose: To investigate the prognostic significance of ribonucleotide reductase small subunit M2 (RRM2) in low- and intermediate-risk prostate cancer (PCa). Materials and methods: A retrospective outcome study was conducted on 164 eligible PCa samples from the City of Hope (n = 90) and the Taipei Medical University (n = 74). The RRM2 protein levels were detected by immunohistochemistry. Biochemical recurrence was assessed using Kaplan-Meier and Cox proportional hazard analyses. Cell invasion assays, Ras/Raf, and matrix metallopeptidase 9 activities were determined to evaluate the role of RRM2 on invasiveness of PCa. Results: Expression of RRM2 was significantly increased in patients with higher Gleason score, who had advanced T stage, and who were margin/capsule positive (P-, capsule-, and stage T1-T2. In patients with Gleason score 4 to 7, the risk of recurrence was proportional to RRM2 protein levels. The prognostic performance of RRM2 was superior to that of pathoclinical factors, including margin/capsule status and T stage. An in vitro study demonstrated that RRM2 could promote tumor invasion activities in PCa cell lines. Suppression of RRM2 reduced the Ras/Raf and matrix metallopeptidase 9 activities. Conclusion: RRM2 plays a critical role in proliferation and invasion of PCa. Adding RRM2 as a biomarker in clinical assessments may increase model precision in predicting recurrence in patients with low-risk PCa.
原文英語
期刊Urologic Oncology: Seminars and Original Investigations
32
發行號1
DOIs
出版狀態已發佈 - 一月 2014

指紋

Prostatic Neoplasms
Recurrence
Capsules
Neoplasm Grading
Metalloproteases
ribonucleotide reductase M2
Proteins
Retrospective Studies
Biomarkers
Immunohistochemistry
Outcome Assessment (Health Care)
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Urology

引用此文

The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers. / Huang, Yasheng; Liu, Xiyong; Wang, Yuan Hung; Yeh, Shauh Der; Chen, Chi Long; Nelson, Rebecca A.; Chu, Peiguo; Wilson, Timothy; Yen, Yun.

於: Urologic Oncology: Seminars and Original Investigations, 卷 32, 編號 1, 01.2014.

研究成果: 雜誌貢獻文章

@article{be7a3b500ee848f68767d04f402934fe,
title = "The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers",
abstract = "Purpose: To investigate the prognostic significance of ribonucleotide reductase small subunit M2 (RRM2) in low- and intermediate-risk prostate cancer (PCa). Materials and methods: A retrospective outcome study was conducted on 164 eligible PCa samples from the City of Hope (n = 90) and the Taipei Medical University (n = 74). The RRM2 protein levels were detected by immunohistochemistry. Biochemical recurrence was assessed using Kaplan-Meier and Cox proportional hazard analyses. Cell invasion assays, Ras/Raf, and matrix metallopeptidase 9 activities were determined to evaluate the role of RRM2 on invasiveness of PCa. Results: Expression of RRM2 was significantly increased in patients with higher Gleason score, who had advanced T stage, and who were margin/capsule positive (P-, capsule-, and stage T1-T2. In patients with Gleason score 4 to 7, the risk of recurrence was proportional to RRM2 protein levels. The prognostic performance of RRM2 was superior to that of pathoclinical factors, including margin/capsule status and T stage. An in vitro study demonstrated that RRM2 could promote tumor invasion activities in PCa cell lines. Suppression of RRM2 reduced the Ras/Raf and matrix metallopeptidase 9 activities. Conclusion: RRM2 plays a critical role in proliferation and invasion of PCa. Adding RRM2 as a biomarker in clinical assessments may increase model precision in predicting recurrence in patients with low-risk PCa.",
keywords = "Biochemical recurrence, Gleason score, Prognostic biomarker, Prostate cancer, Ribonucleotide reductase M2",
author = "Yasheng Huang and Xiyong Liu and Wang, {Yuan Hung} and Yeh, {Shauh Der} and Chen, {Chi Long} and Nelson, {Rebecca A.} and Peiguo Chu and Timothy Wilson and Yun Yen",
year = "2014",
month = "1",
doi = "10.1016/j.urolonc.2013.08.002",
language = "English",
volume = "32",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers

AU - Huang, Yasheng

AU - Liu, Xiyong

AU - Wang, Yuan Hung

AU - Yeh, Shauh Der

AU - Chen, Chi Long

AU - Nelson, Rebecca A.

AU - Chu, Peiguo

AU - Wilson, Timothy

AU - Yen, Yun

PY - 2014/1

Y1 - 2014/1

N2 - Purpose: To investigate the prognostic significance of ribonucleotide reductase small subunit M2 (RRM2) in low- and intermediate-risk prostate cancer (PCa). Materials and methods: A retrospective outcome study was conducted on 164 eligible PCa samples from the City of Hope (n = 90) and the Taipei Medical University (n = 74). The RRM2 protein levels were detected by immunohistochemistry. Biochemical recurrence was assessed using Kaplan-Meier and Cox proportional hazard analyses. Cell invasion assays, Ras/Raf, and matrix metallopeptidase 9 activities were determined to evaluate the role of RRM2 on invasiveness of PCa. Results: Expression of RRM2 was significantly increased in patients with higher Gleason score, who had advanced T stage, and who were margin/capsule positive (P-, capsule-, and stage T1-T2. In patients with Gleason score 4 to 7, the risk of recurrence was proportional to RRM2 protein levels. The prognostic performance of RRM2 was superior to that of pathoclinical factors, including margin/capsule status and T stage. An in vitro study demonstrated that RRM2 could promote tumor invasion activities in PCa cell lines. Suppression of RRM2 reduced the Ras/Raf and matrix metallopeptidase 9 activities. Conclusion: RRM2 plays a critical role in proliferation and invasion of PCa. Adding RRM2 as a biomarker in clinical assessments may increase model precision in predicting recurrence in patients with low-risk PCa.

AB - Purpose: To investigate the prognostic significance of ribonucleotide reductase small subunit M2 (RRM2) in low- and intermediate-risk prostate cancer (PCa). Materials and methods: A retrospective outcome study was conducted on 164 eligible PCa samples from the City of Hope (n = 90) and the Taipei Medical University (n = 74). The RRM2 protein levels were detected by immunohistochemistry. Biochemical recurrence was assessed using Kaplan-Meier and Cox proportional hazard analyses. Cell invasion assays, Ras/Raf, and matrix metallopeptidase 9 activities were determined to evaluate the role of RRM2 on invasiveness of PCa. Results: Expression of RRM2 was significantly increased in patients with higher Gleason score, who had advanced T stage, and who were margin/capsule positive (P-, capsule-, and stage T1-T2. In patients with Gleason score 4 to 7, the risk of recurrence was proportional to RRM2 protein levels. The prognostic performance of RRM2 was superior to that of pathoclinical factors, including margin/capsule status and T stage. An in vitro study demonstrated that RRM2 could promote tumor invasion activities in PCa cell lines. Suppression of RRM2 reduced the Ras/Raf and matrix metallopeptidase 9 activities. Conclusion: RRM2 plays a critical role in proliferation and invasion of PCa. Adding RRM2 as a biomarker in clinical assessments may increase model precision in predicting recurrence in patients with low-risk PCa.

KW - Biochemical recurrence

KW - Gleason score

KW - Prognostic biomarker

KW - Prostate cancer

KW - Ribonucleotide reductase M2

UR - http://www.scopus.com/inward/record.url?scp=84890673363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890673363&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2013.08.002

DO - 10.1016/j.urolonc.2013.08.002

M3 - Article

VL - 32

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -